TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04465578

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sling tension adjustment by classic technique
Description: We will adjust the tension of the sling by using the classic technique (2 fingers between the fascia and the knot)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sling tension adjustment by height of 4 cm
Description: We will adjust the tension of the sling by using the height between the fascia and the knot of 4cm
Study: NCT03772964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetFORMIN Hydrochloride ER
Description: Subjects will be exposed to 500mg, 1000mg, or 1500mg of daily ER Metformin, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetFORMIN Hydrochloride ER
Description: Subjects will be exposed to 500mg, 1000mg, or 1500mg of daily ER Metformin, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetFORMIN Hydrochloride ER
Description: Subjects will be exposed to 500mg, 1000mg, or 1500mg of daily ER Metformin, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be exposed to placebo, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.
Study: NCT01286402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Description: * 150mg, taken orally, taken daily for the 1st 3 days~* 300mg, taken orally, taken daily for the rest of the 8 weeks of drug treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: -Avicel PH 302, Emcocel 50M, Cab-O-Sil M5P, Magnesium Stearate (appearance, taste, and dosing instructions were identical to the bupropion group), i.e., 1 pill orally, taken daily for the 1st 3 days; 2 pills, taken orally, taken daily for the rest of the 8 weeks of drug treatment
Study: NCT02473562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Tablet 1 mg BID
Study: NCT01890746

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytarabine
Description: 100 mg/m2/day continuous IV infusion on Days 1 through 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: 200 mg orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose of the Investigational Product (IP) was to be increased to 300 mg if platelet counts were \<100 Gi/L. IP continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage 100 mg orally once daily (a 50% dose reduction) was used and after 7 days, the dose of IP was increased to 150 mg if platelet counts were \<100 Gi/L.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose given was matching 300 mg Eltrombopag if platelet counts were \<100 Gi/L. Placebo continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage placebo matching 100 mg Eltrombopag orally once daily was used and after 7 days, the placebo matching 150 mg Eltrombopag was given if platelet counts were \<100 Gi/L.
Study: NCT03028103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat is a selective oral small molecule inhibitor of EZH2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 200mg will be orally administered QD for 4 days in order to determine CYP3A4 inhibition when administered concomitantly with tazemetostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Using omeprazole as a probe substrate, 20mg will be orally administered for a total of 5 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C19. Omeprazole is also being used to determine the effect of increased gastric pH on metabolism of tazemetostat.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Using repaglinide as a probe substrate, 25mg will be orally administered for a total of 2 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C8.
Study: NCT03177057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compliance Monitoring
Description: Record behavior

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compliance Monitoring
Description: Record behavior

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Receive health monitoring text messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Receive health monitoring text messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03453567

Intervention type: PROCEDURE
Intervention: Valve Replacement
Description: Aortic valve replacement

Intervention type: PROCEDURE
Intervention: Valve Replacement
Description: Aortic valve replacement

Intervention type: PROCEDURE
Intervention: Valve Replacement
Description: Aortic valve replacement
Study: NCT04116489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forest walk
Description: Participants will be provided with an educational program about the forest and take a guided forest walk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wildlife rehabilitation
Description: Participants will be provided with education on wildlife rehabilitation and assist with wildlife care such as feeding baby animals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wildlife sanctuary observation
Description: Participants will be provided an educational program on wildlife care and accompany park game keepers during animal feeding and will observe iconic wildlife.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bird feeding and watching
Description: Participants will learn about bird identification and safe bird feeding. Bird feeders will be provided at the Soldier On facility for home bird feeding after study conclusion.
Study: NCT01107496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IR Viloxazine
Description: One 50mg immediate-release viloxazine capsule administered orally 3 times a day (150mg total daily dose) for Week 1.~Two 50mg immediate-release viloxazine capsules administered orally 3 times a day (300mg total daily dose) for Weeks 2 to 6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules administered orally 3 times a day
Study: NCT02584647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: PLX3397 is a small molecule that potently and selectively inhibits macrophage colony-stimulating factor receptor (FMS), Kit, and FMS-like tyrosine kinase 3 (Flt3)-internal tandem duplication (ITD) kinases, which regulate key components of the tumor microenvironment and oncogenic variants of these kinases that drive certain tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: PLX3397 is a small molecule that potently and selectively inhibits macrophage colony-stimulating factor receptor (FMS), Kit, and FMS-like tyrosine kinase 3 (Flt3)-internal tandem duplication (ITD) kinases, which regulate key components of the tumor microenvironment and oncogenic variants of these kinases that drive certain tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus is a macrocyclic lactone that binds to tacrolimus (FK506) binding protein 12 and inhibits mammalian target of rapamycin (mTOR) resulting in cell-cycle arrest and apoptosis.~Sirolimus is currently approved as an immunosuppressive agent for organ transplantation and more recently, as a component of cardiac arterial stents because of its potent antiproliferative effects on fibroblasts responsible for restenosis after such a procedure (26) Sirolimus is commonly administered orally on a daily basis, in doses ranging from 2 to 40 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus is a macrocyclic lactone that binds to tacrolimus (FK506) binding protein 12 and inhibits mammalian target of rapamycin (mTOR) resulting in cell-cycle arrest and apoptosis.~Sirolimus is currently approved as an immunosuppressive agent for organ transplantation and more recently, as a component of cardiac arterial stents because of its potent antiproliferative effects on fibroblasts responsible for restenosis after such a procedure (26) Sirolimus is commonly administered orally on a daily basis, in doses ranging from 2 to 40 mg/day.
Study: NCT02473562

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for varenicline)
Description: Tablet 1 mg BID
Study: NCT01555580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Description: Participants will receive one dose of GM-CSF (5 µg/kg) by subcutaneous injection for ten (10) consecutive days. The first dose of GM-CSF will be administered by the subject or caregiver under the observation and direction of the study staff during the baseline visit. The subject or caregiver will administer subsequent injections at home.
Study: NCT01715870

Intervention type: BEHAVIORAL
Intervention: Life style and food habits questionnaire
Study: NCT04666740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV every 3 week. After the first 6 months (8 cycles), on C9D1 Pembrolizumab 400 mg IV every 6 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV every 3 week. After the first 6 months (8 cycles), on C9D1 Pembrolizumab 400 mg IV every 6 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV every 3 week. After the first 6 months (8 cycles), on C9D1 Pembrolizumab 400 mg IV every 6 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg twice day orally daily continuously (POLAR) as a maintenance therapy. After the first 6 months (8 cycles), on C9D1 olaparib 300 mg twice a day orally will be continued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg twice day orally daily continuously (POLAR) as a maintenance therapy. After the first 6 months (8 cycles), on C9D1 olaparib 300 mg twice a day orally will be continued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg twice day orally daily continuously (POLAR) as a maintenance therapy. After the first 6 months (8 cycles), on C9D1 olaparib 300 mg twice a day orally will be continued.
Study: NCT04361487

Intervention type: DEVICE
Intervention: NOVOSTITCH PRO Meniscal Repair System
Description: Standard of care surgery with in which the meniscus is repaired using NOVOSTITCH PRO

Intervention type: DEVICE
Intervention: NOVOSTITCH PRO Meniscal Repair System
Description: Standard of care surgery with in which the meniscus is repaired using NOVOSTITCH PRO
Study: NCT01587196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivitrol
Description: There are monthly injections of depot naltrexone for 3 months.
Study: NCT03177057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01355627

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TachoSil®
Description: Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator. TachoSil® must be applied under aseptic conditions during the closure of the dura.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Current Practice
Description: Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator.~In addition to primary suture, whatever means of dura closure deemed necessary by the investigator may be used with the exception of TachoSil®.
Study: NCT04305756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Low molecular weight heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Low molecular weight heparin
Study: NCT03161262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS-based reminders
Description: The SMS-based reminders consist of sending messages to participants assigned to this study arm reminding them to take their medication and prompting participants to complete surveys. Medication reminders are sent as per the participant's prescribed frequency and weekly surveys allow participants to report their pain level as well as send an image of their surgical site. Beyond pre-determined reminders and surveys sent to patients, the Memora Health platform is interactive and allows patients to text in questions they may have regarding their medications, care, or condition. Participants will receive the messages for 3 months.
Study: NCT05721079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECP (Extracorporeal Photopheresis System)
Description: Patients who are assigned to the ECP group receive treatments by means of the THERAKOS ® CELLEX ® Photopheresis System (Mallinckrodt Pharmaceuticals Inc.) with either double- or single-needle access. During the leukapheretic processing, 1500 ml of whole blood is processed, and peripheral blood mononuclear cells (MCNs) are separated by centrifugation and collected in the buffy coat. 8-methoxypsoralen (Uvadex®, Mallinckrodt Pharmaceuticals Inc.) at a dose of 20 μg/ml is added to the MNC collection bag and cells are irradiated with ultraviolet A light (1.5 J/cm2) in a 1-mm-thick film through a photoactivation plate. After exposure of the cells to the ultraviolet light, the buffy coat is reinfused into the patient.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECP (Extracorporeal Photopheresis System)
Description: Patients who are assigned to the ECP group receive treatments by means of the THERAKOS ® CELLEX ® Photopheresis System (Mallinckrodt Pharmaceuticals Inc.) with either double- or single-needle access. During the leukapheretic processing, 1500 ml of whole blood is processed, and peripheral blood mononuclear cells (MCNs) are separated by centrifugation and collected in the buffy coat. 8-methoxypsoralen (Uvadex®, Mallinckrodt Pharmaceuticals Inc.) at a dose of 20 μg/ml is added to the MNC collection bag and cells are irradiated with ultraviolet A light (1.5 J/cm2) in a 1-mm-thick film through a photoactivation plate. After exposure of the cells to the ultraviolet light, the buffy coat is reinfused into the patient.
Study: NCT01092650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuterated phenanthrene
Description: Deuterated phenanthrene 10 micrograms
Study: NCT03177057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04275570

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational interview
Description: The motivational interview is integrated in a structural theoretical mark. This method is a person-centered counseling style that increases the intrinsic motivation of the patient to behavioral changes through spirit, acceptance, compassion and evocation.
Study: NCT01092650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deuterated phenanthrene
Description: Deuterated phenanthrene 10 micrograms
Study: NCT01356147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dornase alfa
Description: 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
Study: NCT01852305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lab Sleep Study Group
Description: Patients in this group will under go lab sleep study overnight at the sleep clinic.If the patient has severe sleep apnea (AHI\>30) or moderate sleep apnea (AHI\>15 to \<30) with significant co-morbidities (e.g. cardiovascular disease, diabetes), CPAP treatment will be recommended. For mild sleep apnea (AHI\>5 to \<15) or moderate sleep apnea without significant co-morbidities, CPAP will not be required. If patient is not able to tolerate or refuses CPAP, dental device and positional therapy will be recommended.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oximetry
Description: The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI\>10 events/hour will be referred to the sleep medicine specialist.A split- night PSG will be employed to confirm OSA diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night
Study: NCT02544178

Intervention type: RADIATION
Intervention: brain radiotherapy
Description: effect of cerebral radiotherapy on neurocognitive state
Study: NCT03458975

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: Magnetic Resonance Imaging

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Magnetic Resonance Imaging

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Perfusion CT scan
Description: Perfusion Computerized tomography scan
Study: NCT02166801

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Children displaying delayed development and at risk of developing cerebral palsy are continuously followed-up at the children's hospital. There are no strict rules for the frequency of appointments within the usual care program but the families typically meet a physiotherapist every third week during the first 2-3 months, thereafter about once a month. The frequency depends on the family's needs and wishes. If there is a continuous need for therapeutic intervention and need of contact with different professions, the families will be referred to the Habilitation Services when the child is between 8-12 months. The control group will follow this customary procedure in the hospital. The only difference will be the assessment procedure, the sessions with the speech pathologist and that they will get feedback of the children's progress after each examination.
Study: NCT03635697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Auditory Intervention
Description: This intervention is a short audio clip that focuses on the practices and principles of mindfulness. The goal of mindfulness is to bring awareness to a person's physical body as well as their thoughts and feelings.
Study: NCT03695211

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional landmark technique
Description: inject at the midpoint of the posterior border of the sternocleidomastoid muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Precise block technique
Description: inject at the point where the great auricular nerve emerges the posterior border of the sternocleidomastoid muscle
Study: NCT01623804

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low intensity, pulsed ultrasound
Description: 1.5MHz, spatial average-temporal average intensity = 0.03W/cm2, pulsed (burst frequency 1kHz, burst duration 200µm, duty cycle 20%); self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham ultrasound
Description: no ultrasonic energy emitted; self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months
Study: NCT03285919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance Assessment Robot (BAR™)
Description: The BAR™ has got six degrees of freedom (DOF) that interface to the pelvis of a walking subject. Five DOFs (translation of pelvis in sagittal, lateral and vertical directions; pelvic rotation and pelvic list) are actuated and admittance-controlled, providing transparent haptic interaction with negligible power transfer; the remaining DOF (pelvic tilt) is passive. The BAR™ is capable of delivering perturbations in the directions forward/backward and left/right, but for the purpose of this study only outward perturbations in the frontal plane were considered.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balance Assessment Robot (BAR™)
Description: The BAR™ has got six degrees of freedom (DOF) that interface to the pelvis of a walking subject. Five DOFs (translation of pelvis in sagittal, lateral and vertical directions; pelvic rotation and pelvic list) are actuated and admittance-controlled, providing transparent haptic interaction with negligible power transfer; the remaining DOF (pelvic tilt) is passive. The BAR™ is capable of delivering perturbations in the directions forward/backward and left/right, but for the purpose of this study only outward perturbations in the frontal plane were considered.
Study: NCT01356147

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: No therapy will be given to placebo arm
Study: NCT02245659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous Positive Airway Pressure

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal dilator strip
Description: Nasal dilator strip to be worn nightly
Study: NCT00974272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Single subcutaneous injection (10 μg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Single subcutaneous injection
Study: NCT03458975

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Perfusion CT scan
Description: Perfusion Computerized tomography scan

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Contrast enhanced ultrasound
Description: Contrast enhanced ultrasound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contrast enhanced ultrasound
Description: Contrast enhanced ultrasound

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sonoporation
Description: Gaseous microbubbles (Sonovue) combinated with Ultrasounds
Study: NCT04894695

Intervention type: DIAGNOSTIC_TEST
Intervention: biomarkers detection in different groups
Description: Biomarkers of urine exosomes in different groups were identified by sequencing technology，then biomarkers were validated using urine samples of different groups

Intervention type: DIAGNOSTIC_TEST
Intervention: biomarkers detection in different groups
Description: Biomarkers of urine exosomes in different groups were identified by sequencing technology，then biomarkers were validated using urine samples of different groups